Showing 1 of 1 PublicationsWhat have we learnt from Vioxx?Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? The BMJ 2007, 334: 120. PMID: 17235089, PMCID: PMC1779871, DOI: 10.1136/bmj.39024.487720.68.Commentaries, Editorials and LettersCitations 218 CITATIONS 218 Total citations 32 Recent citations 47 Field Citation Ratio 2.88 Relative Citation Ratio Altmetric MeSH Keywords and ConceptsMeSH KeywordsCardiovascular DiseasesCompensation and RedressCyclooxygenase 2 InhibitorsDrug IndustryHumansInterprofessional RelationsLactonesRisk FactorsScientific MisconductSulfonesTime FactorsUnited KingdomUnited StatesConceptsCardiovascular eventsUK patientsDownload Full List
What have we learnt from Vioxx?Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? The BMJ 2007, 334: 120. PMID: 17235089, PMCID: PMC1779871, DOI: 10.1136/bmj.39024.487720.68.Commentaries, Editorials and LettersCitations 218 CITATIONS 218 Total citations 32 Recent citations 47 Field Citation Ratio 2.88 Relative Citation Ratio Altmetric MeSH Keywords and ConceptsMeSH KeywordsCardiovascular DiseasesCompensation and RedressCyclooxygenase 2 InhibitorsDrug IndustryHumansInterprofessional RelationsLactonesRisk FactorsScientific MisconductSulfonesTime FactorsUnited KingdomUnited StatesConceptsCardiovascular eventsUK patients